Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review

References

• Bremer J. The role of carnitine in intracellular metabolism. J Clin Chem Clin Biochem. 1990;28(5):297–301.2199593
   PubMedGoogle Scholar
• Colucci WJ, Grandour RD. Carnitine acyltransferase: a review of its biology, enzymology and bioorganic chemistry. Bioorg Chem. 1988;16:307–334. doi:10.1016/0045-2068(88)90018-1
   Web of Science ®Google Scholar
• Manfridi A, Forloni GL, Arrigoni-Martelli E, Mancia M. Culture of dorsal root ganglion neurons from aged rats: effects of acetyl-L carnitine and NGF. Int J Dev Neurosci. 1992;10(4):321–329. doi:10.1016/0736-5748(92)90021-Q1414444
   PubMed Web of Science ®Google Scholar
• Taglialatela G, Angelucci L, Ramacci MT, Werrbach-Perez K, Jackson GR, Perez-Polo JR. Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor. Brain Res Dev Brain Res. 1991;59(2):221–230.1655307
   PubMedGoogle Scholar
• Angelucci L, Ramacci MT, Taglialatela G, et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neurosci Res. 1988;20(4):491–496. doi:10.1002/jnr.4902004132846861
   PubMed Web of Science ®Google Scholar
• Fernandez E, Pallini R, Gangitano C, et al. Effects of L-carnitine, L-acetyl carnitine and gangliosides on the regeneration of the transected sciatic nerve in rats. Neurol Res. 1989;11(1):57–62. doi:10.1080/01616412.1989.117398632565553
   PubMedGoogle Scholar
• Hart AM, Wiberg M, Terenghi G. Pharmacological enhancement of peripheral nerve regeneration in the rat by systemic acetyl-L carnitine treatment. Neurosci Lett. 2002;334(3):181–185. doi:10.1016/S0304-3940(02)00982-512453625
   PubMed Web of Science ®Google Scholar
• Virmani MA, Biselli R, Spadoni A, et al. Protective actions of L-carnitine and acetyl-L-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitors. Pharmacol Res. 1995;32(6):383–389. doi:10.1016/S1043-6618(05)80044-18736490
   PubMed Web of Science ®Google Scholar
• Hart AM, Wiberg M, Youle M, Terenghi G. Systemic acetyl-L carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma. Exp Brain Res. 2002;145(2):182–189. doi:10.1007/s00221-002-1100-212110958
   PubMed Web of Science ®Google Scholar
• Sima AA, Ristic H, Merry A, et al. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest. 1996;97(8):1900–1907. doi:10.1172/JCI1186218621774
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Ghelardini C, Calvani M, et al. Protective effect of acetyl-l-carnitine on the apoptotic pathway of peripheral neuropathy. Eur J Neurosci. 2007;26(4):820–827. doi:10.1111/j.1460-9568.2007.05698.x17714181
   PubMed Web of Science ®Google Scholar
• Mansour HH. Protective role of carnitine ester against radiation induced oxidative stress in rats. Pharmacol Res. 2006;54(3):165–171. doi:10.1016/j.phrs.2006.04.00316757176
   PubMed Web of Science ®Google Scholar
• Imperato A, Ramacci MT, Angelucci L. Acetyl-L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neurosci Lett. 1989;107(1–3):251–255. doi:10.1016/0304-3940(89)90826-42616037
   PubMed Web of Science ®Google Scholar
• Li S, Li Q, Li Y, et al. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10(3):e0119479. doi:10.1371/journal.pone.011947925751285
   PubMed Web of Science ®Google Scholar
• Cruccu G, Di Stefano G, Fattapposta F, et al. L-Acetyl-carnitine in patients with carpal tunnel syndrome: effects on nerve protection, hand function and pain. CNS Drugs. 2018;32(3):303. doi:10.1007/s40263-018-0493-929441455
   PubMed Web of Science ®Google Scholar
• Chiechio S, Copani A, Gereau RW 4th, Nicoletti F. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs. 2007;21 Suppl 1:31–8; discussion 45–6. doi:10.2165/00023210-200721001-00005
   Web of Science ®Google Scholar
• Notartomaso S, Mascio G, Bernabucci M, et al. Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain. Mol Pain. 2017;13:1744806917697009. doi:10.1177/174480691769700928326943
   PubMed Web of Science ®Google Scholar
• Truini A, Piroso S, Pasquale E, et al. N-acetyl-cysteine, a drug that enhances the endogenous activation of group-II metabotropic glutamate receptors, inhibits nociceptive transmission in humans. Mol Pain. 2015;11:14. doi:10.1186/s12990-015-0009-225889381
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Ghelardini C, Calvani M, et al. Neuroprotective effects of acetyl-L-carnitine on neuropathic pain and apoptosis: a role for the nicotinic receptor. J Neurosci Res. 2009;87(1):200–207. doi:10.1002/jnr.2181518709658
   PubMed Web of Science ®Google Scholar
• Bartolini A, Di Cesare Mannelli L, Ghelardini C. Analgesic and antineuropathic drugs acting through central cholinergic mechanisms. Recent Pat CNS Drug Discov. 2011;6(2):119–140. doi:10.2174/15748891179593390121585331
   PubMedGoogle Scholar
• Pessoa BL, Escudeiro G, Nascimento OJ. Emerging treatments for neuropathic pain. Curr Pain Headache Rep. 2015;19(12):56. doi:10.1007/s11916-015-0530-z26530058
   PubMed Web of Science ®Google Scholar
• American Academy of Neurology. Edition Clinical Practice Guideline Process Manual. 2017 Available from: https://www.aan.com/siteassets/home-page/policy-and-guidelines/guidelines/about-guidelines/17guidelineprocman_pg.pdf. Accessed 21 March, 2019. 
   Google Scholar
• Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111. doi:10.1002/jrsm.1226061376
   PubMed Web of Science ®Google Scholar
• Sima AA, Calvani M, Mehra M, Amato A, Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care. 2005;28(1):89–94.15616239
   PubMed Web of Science ®Google Scholar
• De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D. 2002;3(4):223–231.12455197
   PubMedGoogle Scholar
• Li S, Chen X, Li Q, et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig. 2016;7(5):777–785. doi:10.1111/jdi.12493
   Web of Science ®Google Scholar
• Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5(12):e14433. doi:10.1371/journal.pone.001443321203440
   PubMed Web of Science ®Google Scholar
• Youle M, Osio M, ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007;8(4):241–250. doi:10.1111/j.1468-1293.2007.00467.x17461852
   PubMed Web of Science ®Google Scholar
• Hart AM, Wilson AD, Montovani C, et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS. 2004;18(11):1549–1560.15238773
   PubMed Web of Science ®Google Scholar
• Valcour V, Yeh TM, Bartt R, et al. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Med. 2009;10(2):103–110. doi:10.1111/j.1468-1293.2008.00658.x19200173
   PubMed Web of Science ®Google Scholar
• Osio M, Muscia F, Zampini L, et al. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst. 2006;11(1):72–76. doi:10.1111/j.1085-9489.2006.00066.x16519785
   PubMed Web of Science ®Google Scholar
• Scarpini E, Sacilotto G, Baron P, et al. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst. 1997;2(3):250–252.10975731
   PubMedGoogle Scholar
• Herzmann C, Johnson MA, Youle M. Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials. 2005;6(6):344–350. doi:10.1310/CH1N-YBNU-G3CU-JBXR16566084
   PubMed Web of Science ®Google Scholar
• Sun Y, Shu Y, Liu B, et al. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. Exp Ther Med. 2016;12(6):4017–4024. doi:10.3892/etm.2016.387128105133
   PubMed Web of Science ®Google Scholar
• Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori. 2005;91(2):135–138.15948540
   PubMed Web of Science ®Google Scholar
• Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005;41(12):1746–1750. doi:10.1016/j.ejca.2005.04.02816039110
   PubMed Web of Science ®Google Scholar
• Hershman DL, Unger JM, Crew KD, et al. Randomized placebo-controlled trial of acetyl-L-carnitine for prevention of taxane-induced neuropathy during adjuvant breast cancer therapy. J Clin Oncol. 2013;31(20):2627–2633. doi:10.1200/JCO.2012.44.873823733756
   PubMed Web of Science ®Google Scholar
• Campone M, Berton-Rigaud D, Joly-Lobbedez F, et al. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. Oncologist. 2013;18(11):1190–1191. doi:10.1634/theoncologist.2013-006124105751
   PubMed Web of Science ®Google Scholar
• Callander N, Markovina S, Eickhoff J, et al. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the wisconsin oncology network. Cancer Chemother Pharmacol. 2014;74(4):875–882.25168296
   PubMed Web of Science ®Google Scholar
• Truini A, Padua L, Biasiotta A, et al. Differential involvement of A-delta and A-beta fibres in neuropathic pain related to carpal tunnel syndrome. Pain. 2009;145(1–2):105–109. doi:10.1016/j.pain.2009.05.02319535205
   PubMed Web of Science ®Google Scholar
• De Grandis D, Santoro L, Di Benedetto P. L-acetylcarnitine in the treatment of patients with peripheral neuropathies: a short term, double-blind clinical study of 426 patients. Clin Drug Investig. 1995;10(6):317–322. doi:10.2165/00044011-199510060-00001
   Web of Science ®Google Scholar
• Fritz IB. Action of carnitine on long chain fatty acid oxidation by liver. Am J Physiol. 1959;197:297–304. doi:10.1152/ajplegacy.1959.197.1.21713825279
   PubMed Web of Science ®Google Scholar
• Tamamoğullari N, Siliğ Y, Içağasioğlu S, Atalay A. Carnitine deficiency in diabetes mellitus complications. J Diabetes Complications. 1999;13(5–6):251–253.10764998
   PubMed Web of Science ®Google Scholar
• Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS. 1997;11(2):185–190.9030365
   PubMed Web of Science ®Google Scholar
• Hur J, Sullivan KA, Callaghan BC, Pop-Busui R, Feldman EL. Identification of factors associated with sural nerve regeneration and degeneration in diabetic neuropathy. Diabetes Care. 2013;36(12):4043–4049. doi:10.2337/dc12-253024101696
   PubMed Web of Science ®Google Scholar